(Reuters) -Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)
Comments